75.06  -1.78 (-2.32%)		11-04 16:00
Open: 75.315 High: 76.25 Volume: 145,909		Pre. Close: 76.84 Low: 71.55 Market Cap: 830(M)

Short term
Mid term
Targets	6-month :	95.86	1-year :	111.97
Resists	First :	82.08	Second :	95.86
Pivot price	74.85
Supports	First :	68.73	Second :	60.49
MAs	MA(5) :	77.06	MA(20) :	74.36
	MA(100) :	49.15	MA(250) :	31.48
MACD	MACD :	3.5	Signal :	3.8
%K %D	K(14,3) :	66.6	D(3) :	79.7
RSI	RSI(14): 56.3
52-week	High :	82.08	Low :	11.17

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ PVLA ] has closed below upper band by 48.0%. Bollinger Bands are 16.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	76.33 - 76.74	76.74 - 77.09
Low:	70.57 - 71.08	71.08 - 71.49
Close:	74.27 - 75.07	75.07 - 75.73

Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. Its lead product candidate is QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin) that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Wayne, Pennsylvania.

Tue, 04 Nov 2025
Palvella Therapeutics (NASDAQ:PVLA) Sees Strong Trading Volume - Here's Why - MarketBeat

Tue, 04 Nov 2025
Palvella Therapeutics to Host Third Quarter 2025 Financial - GlobeNewswire

Mon, 27 Oct 2025
Palvella Therapeutics Advances Phase 3 Study on QTORIN Gel for Rare Disease - TipRanks

Mon, 27 Oct 2025
Is Palvella Therapeutics (NASDAQ:PVLA) Weighed On By Its Debt Load? - simplywall.st

Mon, 13 Oct 2025
Palvella Therapeutics (NASDAQ:PVLA) Sets New 12-Month High - Time to Buy? - MarketBeat

Mon, 13 Oct 2025
U.S. Food and Drug Administration Awards Year Two Proceeds from Orphan Products Grant Supporting Palvella Therapeutics’ Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations - Yahoo Finance

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	11 (M)
Shares Float	6 (M)
Held by Insiders	22.8 (%)
Held by Institutions	55.3 (%)
Shares Short	1,220 (K)
Shares Short P.Month	689 (K)

EPS	-2.53
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	4.32
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-37.3 %
Return on Equity (ttm)	-151.2 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	-20 (M)
Levered Free Cash Flow	-14 (M)

PE Ratio	-29.67
PEG Ratio	0
Price to Book value	17.37
Price to Sales	0
Price to Cash Flow	-40.82

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.